Results 161 to 170 of about 2,013,224 (205)
Some of the next articles are maybe not open access.
Therapy of the Malignant Carcinoid Syndrome
Annals of Internal Medicine, 1965Excerpt The therapy of the malignant carcinoid syndrome presents a unique challenge to physicians caring for patients with this unusual disease.
openaire +2 more sources
Metastatic Carcinoid Tumors and the Malignant Carcinoid Syndrome
Annals of the New York Academy of Sciences, 1994Patients with metastatic carcinoid tumors and the malignant carcinoid syndrome have benefited immensely from diagnostic and therapeutic advances during the past decade. Magnetic resonance imaging and whole body scintigraphy with radiolabelled analogues of somatostatin have improved our ability to diagnose, detect, stage and follow response to therapy ...
openaire +2 more sources
Archives of Internal Medicine, 1966
SINCE the early descriptions of the carcinoid syndrome, 1-4 it has been assumed that the associated hyperserotonemia is responsible for the symptoms and development of the cardiac lesions. These lesions, which appear mainly on the right side of the heart, are characterized by subendocardial proliferation of fibrous tissue resulting in thickening of the
openaire +1 more source
SINCE the early descriptions of the carcinoid syndrome, 1-4 it has been assumed that the associated hyperserotonemia is responsible for the symptoms and development of the cardiac lesions. These lesions, which appear mainly on the right side of the heart, are characterized by subendocardial proliferation of fibrous tissue resulting in thickening of the
openaire +1 more source
Gastrointestinal carcinoids and the malignant carcinoid syndrome.
Surgery, gynecology & obstetrics, 1981The records of 59 patients with gastrointestinal carcinoid tumors at The New York Hospital from 1948 to 1978 were reviewed. Forty-seven instances were diagnosed surgically; 12 were identified on autopsy specimens. The average age at diagnosis was 55.8 years. No association with duodenal ulcer or carcinoma could be made. The appendix was the mose common
H, Beaton, W, Homan, P, Dineen
openaire +1 more source
Abdominal Crisis in the Malignant Carcinoid Syndrome
Archives of Internal Medicine, 1966EPISODES of acute abdominal pain during the course of the malignant carcinoid syndrome often present a major challenge to physicians caring for patients with this unique disease. The primary tumor (usually in the small intestine) rarely causes symptoms until widespread metastases occur.
openaire +2 more sources
Malignant carcinoid syndrome: Two case reports
Journal of Surgical Oncology, 1980AbstractThe malignant carcinoid syndrome (MCS) is a rare complication of malignant carcinoid neoplasms, fewer than 200 cases having been reported since its description by Thorson in 1954. Its signs and symptoms vary with the site of the primary neoplasm, and MCS is now recognized as one member of the large family of endocrine tumors ‐ APUDOMAS ...
J L, Spann, D, Van Wormer, M E, Sandlin
openaire +2 more sources
Cancer, 1991
Sixteen patients with metastatic neuroendocrine tumors and the malignant carcinoid syndrome were treated with cyproheptadine (Periactin, Merck, Sharp & Dohme, West Point, PA) at maximum tolerable doses that ranged from 12 to 48 mg daily. Usual side effects were mild sedation and dry mouth, but three patients found it impossible to sustain treatment due
C G, Moertel, L K, Kvols, J, Rubin
openaire +2 more sources
Sixteen patients with metastatic neuroendocrine tumors and the malignant carcinoid syndrome were treated with cyproheptadine (Periactin, Merck, Sharp & Dohme, West Point, PA) at maximum tolerable doses that ranged from 12 to 48 mg daily. Usual side effects were mild sedation and dry mouth, but three patients found it impossible to sustain treatment due
C G, Moertel, L K, Kvols, J, Rubin
openaire +2 more sources
The occurrence of malignant carcinoid syndrome in patients with carcinoid tumors.
Bratislavske lekarske listy, 2002The carcinoid syndrome occurs in about 10% of patients with carcinoid tumors.The main objective of the present study was to determine the presence of the carcinoid syndrome in a group of patients with carcinoid tumor.35 pts with carcinoid tumors (group A--24 pts with metastatic disease, group B--11 pts after resection of the primary tumor with no ...
S, Kinova +7 more
openaire +1 more source
Effect of Melphalan in the Malignant Carcinoid Syndrome
Archives of Internal Medicine, 1969Nine trials of the antitumor chemotherapeutic agent, melphalan (L-phenylalanine mustard; Alkeran) were carried out in eight patients with the malignant carcinoid syndrome. In six trials, this drug was given on a low-dose, daily basis. In three of these trials, there was definite evidence of antitumor effect as determined by measurable decreases in ...
openaire +1 more source
The Malignant Carcinoid Syndrome (Argentaffinoma)
American Journal of Ophthalmology, 1957openaire +2 more sources

